OC.10.3 THE EFFECTIVENESS OF USTEKINUMAB AND VEDOLIZUMAB AS THIRD-LINE THERAPY IN PATIENTS WITH REFRACTORY CROHN'S DISEASE. (May 2022) - Macaluso, F.S.; Grova, M.; Saladino, M.; Demarzo, M.G.; Privitera, A.C.; Giangreco, E.; Garufi, S.; Renna, S.; Casà, A.; Ventimiglia, M.; Cappello, M.; Fries, W.; et al.